Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 6;12:4137. doi: 10.1038/s41467-021-24412-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, b Representative dynamic changes of body temperature in patients with PES. Treated with tocilizumab (a), treated without tocilizumab (b). c Representative images of skin rash from the ear of a PES patient before and after treatment with tocilizumab (similar results were obtained in all patients). d Body temperature of patients with PES before and after treatment with tocilizumab. Paired t test (two-sided) (n = 11, p = 4e-6). e Dynamic changes of neutrophils in PES patients treated with tocilizumab. f The probability of nonrelapse mortality in tocilizumab group and the retrospective group. The probability of nonrelapse mortality was performed by the cumulative incidence of competing events and Gray test. ***p < 0.001. TCZ, tocilizumab. Source data are provided as a Source Data file.